SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc

NEW YORK, Aug. 4, 2022

If you own ChemoCentryx shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslaw.co/news-and-cases/ccxi 
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7^th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) ChemoCentryx's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $52.00 per-share merger consideration adequately compensates ChemoCentryx's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the merger consideration is below the $64.50 median price target set by analysts, and at least one analyst set a price target for the Company of $106 per share, $54.00 above the per-share merger consideration.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-chemocentryx-inc-301600333.html